Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.61 |
| ▸ | LPL | P06858 | 7/20 | 0.61 |
| ▸ | PGR | P06401 | 6/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435465 | 1.00 | LIPG (0.61) | LIPGLPLPGRARESR2 | |
| SCHEMBL18305771 | 0.90 | LIPG (0.46) | LIPGLPLPGRARCLK4 | |
| SCHEMBL23020133 | 0.87 | LIPG (0.44) | LIPGLPLPGRARCLK4 | |
| SCHEMBL30040595 | 0.86 | LIPG (0.55) | LIPGLPLCLK4 | |
| SCHEMBL23383843 | 0.86 | LIPG (0.55) | LIPGLPLCLK4 | |
| SCHEMBL15301291 | 0.85 | LIPG (0.53) | LIPGLPLPGRARESR2 | |
| SCHEMBL25709639 | 0.84 | LIPG (0.53) | LIPGLPLCLK4 | |
| SCHEMBL22652888 | 0.84 | LIPG (0.62) | LIPGLPLESR2 | |
| SCHEMBL15496904 | 0.84 | LIPG (0.62) | LIPGLPLESR2 | |
| SCHEMBL15301292 | 0.84 | LIPG (0.62) | LIPGLPLESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4346357-A1 | SEMICONDUCTING MATERIAL, PROCESS FOR PREPARING A LAYER OF THE SEMICONDUCTING MATERIAL, ORGANIC SEMICONDUCTING DEVICE COMPRISING THE ORGANIC SEMICONDUCTING MATERIAL, DISPLAY DEVICE COMPRISING THE ORGANIC SEMICONDUCTING DEVICE AND COMPOUND | Novaled GmbH (DE) | 2024-04-03 | — | — | EP | disclosed |
| US-20230167097-A1 | HETEROCYCLIC COMPOUND HAVING CYANO-SUBSTITUTION | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167097-A1 | HETEROCYCLIC COMPOUND HAVING CYANO-SUBSTITUTION | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
| CN-111788192-B | Heterocyclic compound and organic light-emitting device using same | 株式会社LG化学 | 2023-05-12 | — | — | CN | disclosed |
| EP-3455328-B1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3455328-B1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2020-03-04 | — | — | EP | disclosed |
| US-20190177617-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2019-06-13 | — | — | US | disclosed |
| EP-3455328-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | Merck Patent GmbH (DE) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017194665-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017194665-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167097-A1 | HETEROCYCLIC COMPOUND HAVING CYANO-SUBSTITUTION | KCNH1, MCM4, MCM2 | LIPG 4465/4885LPL 4349/4885PGR 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.